Cutaneous Squamous Cell Cancer clinical trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer

This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.

Study of EVOLVE104 for advanced bladder and squamous cell cancers

This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.

Safety Study of KUP-101A in Advanced Solid Tumors

This is an early-stage study testing a new drug called KUP-101A in patients with advanced solid cancers (like lung, colon, or breast cancer) that haven't responded to standard treatments. The drug works by activating the immune system to fight cancer.

Testing cosibelimab for advanced skin cancer in specific patients

This trial tests an immunotherapy drug called cosibelimab for patients with advanced cutaneous squamous cell carcinoma who have either had a kidney transplant or have a blood cancer like lymphoma or myeloma. The goal is to see if it can shrink tumors when surgery or radiation is not an option.

Microneedle skin treatment plus doxorubicin for skin cancer

This early-phase study tests whether delivering chemotherapy through tiny skin needles (microneedles) can shrink or control cutaneous squamous cell cancer (cSCC) that can be surgically treated. Because it’s Phase 1/2, the main goals are to check safety and find the best way to deliver the treatment.

Radiation plus atezolizumab for advanced skin cancer

This Phase 1 trial studies adding atezolizumab (an immune therapy) to radiation for people with hard-to-remove or borderline-resectable cutaneous squamous cell carcinoma (cSCC). The goal is to see whether this combination can better control the cancer and whether the treatment is safe.

Cemiplimab before and after surgery for high-risk skin cancer

This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.

Ultra-short immunotherapy before surgery for skin cancer

This trial tests a very short course of immunotherapy (nivolumab) before standard surgery for patients with certain types of advanced or hard-to-treat skin cancer (cutaneous squamous cell carcinoma). The goal is to see if this approach can reduce the need for extensive or disfiguring surgery.

Nivolumab and relatlimab before surgery for skin cancer

This trial tests if two immunotherapy drugs, nivolumab and relatlimab, given before surgery can help shrink a type of skin cancer called cutaneous squamous cell carcinoma. It's for people whose cancer can be removed with surgery.

Sentinel node biopsy for high-risk skin cancer of the head and neck

This trial is testing whether a procedure called sentinel lymph node biopsy (SLNB) can help manage high-risk skin cancer on the head and neck that has not spread to lymph nodes. It is for people whose skin cancer is considered high-risk due to features like size, depth, or location, and who are able to have surgery.

Radiation for skin cancer that spread to neck lymph nodes

This trial tests a focused radiation treatment after surgery for people with a common skin cancer (squamous cell carcinoma) that has spread to the lymph nodes in the neck or near the ear. The goal is to see if this approach can prevent the cancer from coming back.

Study of Ivonescimab for advanced skin or prostate cancer

This study tests a new immunotherapy medicine, ivonescimab, in people with advanced skin cancer or advanced prostate cancer. It looks at how safe and effective the drug is.

Ivonescimab before surgery for head and neck cancer

This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.

Blood test for immune markers in skin cancer patients on cemiplimab

This trial is testing whether a new blood test can predict how well the drug cemiplimab works for skin cancer and if it causes side effects. It may help doctors better match treatments to patients.

Study of L19IL2 and L19TNF for advanced skin cancer

This trial tests a combination of two drugs, L19IL2 and L19TNF, which are injected directly into skin tumors. It is for patients with advanced cutaneous squamous cell carcinoma that has not responded to or cannot tolerate immune checkpoint inhibitor therapy.

Studying insurance for skin cancer treatment

This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.

Testing camonsertib with radiation for returning head and neck cancer

This study tests whether adding the drug camonsertib to radiation therapy can help people whose head and neck cancer has come back in a spot that was already treated with radiation. Camonsertib is an experimental drug that may help radiation work better.

Testing cetuximab plus pembrolizumab for advanced head and neck cancer

This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).

Testing IDP-001 for advanced solid tumors

This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.

Testing an esophagus sponge test for early cancer detection

This study checks whether a special sponge you swallow (EsophaCap) can help detect early esophageal cancer—or help sort out concerning symptoms. You may be contacted again 1–2 weeks later for a short interview.

Remote hearing test for head and neck cancer patients on cisplatin or radiation

This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.

HER2-targeted oncolytic virus plus custom immune cells for solid cancers

This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).

PDT with immunotherapy and chemo for head and neck cancer

This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.